NCT04975308: A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Endocrine (Hormone Therapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progression on or after an aromatase inhibitor alone or in combination with a CDK4/6 inhibitor
Exclusions: Patients with prior treatment of chemotherapy (except for neoadjuvant/ adjuvant chemotherapy, fulvestrant, or any investigational-ER-directed therapy (including SERDs & non-SERDs), or any PI3K-, mTOR- or AKT- inhibitor; Patients with symptomatic or untreated brain metastasis; Patients with leptomeningeal disease

Comments are closed.

Up ↑